Divis Laboratories is currently trading at Rs. 1028.25, up by 9.95 points or 0.98% from its previous closing of Rs. 1018.30 on the BSE.
The scrip opened at Rs. 1028.95 and has touched a high and low of Rs. 1044.90 and Rs. 1017.85 respectively. So far 50948 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1193.80 on 21-Nov-2016 and a 52 week low of Rs. 533.10 on 29-May-2017.
Last one week high and low of the scrip stood at Rs. 1060.00 and Rs. 985.00 respectively. The current market cap of the company is Rs. 27306.10 crore.
The promoters holding in the company stood at 52.07%, while institutions and non-institutions held 32.45% and 15.48% respectively.
Divis Laboratories has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its Unit-II, located at Visakhapatnam, Andhra Pradesh, as closure of audit by USFDA.
Earlier in September, the company's Unit-II was inspected by USFDA wherein a Form-483 was issued with 6 observations.
Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1620.50 |
Dr. Reddys Lab | 6171.85 |
Cipla | 1494.65 |
Zydus Lifesciences | 1013.75 |
Lupin | 1617.85 |
View more.. |